Borges Virginia F, Hu Junxiao, Young Chloe, Maggard Jaron, Parris Hannah J, Gao Dexiang, Lyons Traci R
Young Women's Breast Cancer Translational Program, University of Colorado Cancer Center, Aurora, CO USA.
Division of Medical Oncology, University of Colorado, Anschutz Medical Center, Aurora, CO USA.
NPJ Breast Cancer. 2020 Oct 19;6:56. doi: 10.1038/s41523-020-00198-1. eCollection 2020.
Breast cancer is a global health threat and cases diagnosed in women during the years after childbirth, or postpartum breast cancers (PPBCs), have high risk for metastasis. In preclinical murine models, semaphorin 7a (SEMA7A) drives the metastatic potential of postpartum mammary tumors. Thus, we hypothesize that SEMA7A may drive metastasis of PPBC in women. We report that SEMA7A protein expression is increased in PPBCs compared to their nulliparous counterparts in our University of Colorado cohort. Additionally, tumors from PPBC patients with involved lymph nodes and lymphovascular invasion were higher on average suggesting a potential role for SEMA7A as a prognostic biomarker. Consistent with this hypothesis we identify a level of SEMA7A expression in tumors that can predict for recurrence. We propose SEMA7A as a potential biomarker and therapeutic target for PPBC patients, who currently lack strong predictors of outcome and unique targeted therapy options.
乳腺癌是一种全球性的健康威胁，在产后几年被诊断出的女性乳腺癌病例，即产后乳腺癌（PPBC），具有很高的转移风险。在临床前小鼠模型中，信号素7a（SEMA7A）驱动产后乳腺肿瘤的转移潜能。因此，我们假设SEMA7A可能驱动女性PPBC的转移。我们报告称，在科罗拉多大学队列中，与未生育的对应者相比，PPBC中SEMA7A蛋白表达增加。此外，有淋巴结受累和淋巴管浸润的PPBC患者的肿瘤平均水平更高，这表明SEMA7A作为一种预后生物标志物具有潜在作用。与这一假设一致，我们确定了肿瘤中SEMA7A的表达水平，其可以预测复发。我们提出SEMA7A作为PPBC患者的潜在生物标志物和治疗靶点，这些患者目前缺乏强有力的预后预测指标和独特的靶向治疗选择。
